Thymmune, M13 win Future Innovator Prize

By The Science Advisory Board staff writers

November 3, 2021 -- Astellas Venture Management, a subsidiary of Astellas Pharma, and LabCentral announced that Thymmune Therapeutics and M13 Therapeutics are the winners of the Future Innovator Prize.

The prize, which is sponsored by Astellas, is offered to entrepreneurial scientists or emerging biotechnology startups. The winners receive one year of use at LabCentral's lab facility in Cambridge, MA, and access to Astellas' R&D capabilities and business leaders.

Thymmune Therapeutics is applying its proprietary thymic engineering platform to develop and commercialize cell therapy products. M13 Therapeutics is working to overcome the limitations of current gene therapies by harnessing phage-derived particles.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.